The patient-breast cancer care pathway: how could it be optimized? BMC Cancer 2015;15:394.Baffert S, Hoang HL, Bredart A, et al. The patient-breast cancer care pathway: how could it be optimized? BMC Cancer. 2015;15:394.Baffert S, Hoang HL, Bredart A, et al. The patient-breast ...
Description of BC care pathway patterns BC care pathways in the two years after the first treatment were identified for the 626 women working at BC diagnosis. Five patterns were determined (Fig. 2): “Surgery” (S, n = 201) when treatment was limited to curative BC surgery; “Surgery...
Typically, women in South Africa (SA) are diagnosed with breast cancer when they self-present with symptoms to health facilities. The aim of this study was to determine the pathway that women follow to breast cancer care and factors associated with this journey. A cross-sectional study was con...
Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report A transposon screen identifies enhancement of NF-κB pathway as a mechanism of resistance to eribulin Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with pro...
3.3.3. Dendritic cells (DCs)–based cancer vaccines Dendritic cells regulate immune tolerance and are involved in initiation of anti-tumour effects, by presenting TAAs to T lymphocytes through the MHC pathway [73]. Moreover, DCs have crucial roles in controlling antibody-based responses as they ...
IGF1R signaling results in activation of downstream effectors of the AKT-pathway and MAPK-pathway that function to control mRNA translation in breast cancer [4], [7]. However, the extent to which AIB1 participates in IGF-I stimulated mRNA translation in breast cancer is not known. The ...
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfor...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
Agency for Healthcare Research and Quality; 2024. AHRQ publication 23-05303-EF-2. 13. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. ...
Pathway Studio Portico ProQuest Reaxys SCImago SCOPUS Science Citation Index Expanded (SCIE) Semantic Scholar TD Net Discovery Service UGC-CARE List (India) Wanfang Copyright information Rights and permissions Editorial policies © Springer Science+Business Media, LLC, part of Springer Nature...